Premphase 14/14 is a drug owned by Wyeth Pharmaceuticals Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 17, 2015. Details of Premphase 14/14's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5547948 | Controlled release of steroids from sugar coatings |
Jan, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Premphase 14/14 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Premphase 14/14's family patents as well as insights into ongoing legal events on those patents.
Premphase 14/14's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Premphase 14/14's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 17, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Premphase 14/14 Generics:
There are no approved generic versions for Premphase 14/14 as of now.
Alternative Brands for Premphase 14/14
There are several other brand drugs using the same active ingredient (Estrogens, Conjugated; Medroxyprogesterone Acetate) as Premphase 14/14. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Wyeth Pharms |
|
About Premphase 14/14
Premphase 14/14 is a drug owned by Wyeth Pharmaceuticals Llc. Premphase 14/14 uses Estrogens, Conjugated; Medroxyprogesterone Acetate as an active ingredient. Premphase 14/14 was launched by Wyeth Pharms in 1995.
Approval Date:
Premphase 14/14 was approved by FDA for market use on 17 November, 1995.
Active Ingredient:
Premphase 14/14 uses Estrogens, Conjugated; Medroxyprogesterone Acetate as the active ingredient. Check out other Drugs and Companies using Estrogens, Conjugated; Medroxyprogesterone Acetate ingredient
Dosage:
Premphase 14/14 is available in tablet form for oral-28 use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.625MG,0.625MG;N/A,5MG | TABLET | Prescription | ORAL-28 |